Background Baricitinib and dexamethasone have randomised trials supporting their use for
the treatment of patients with COVID-19. We assessed the combination of baricitinib plus …

… of the now termed coronavirus disease (COVID-19), which can … high-dose corticosteroid
treatment, as occurs in COVID-19, may … such as delirium have been rarely reported in adults [6]. …

… The Food and Drug Administration has authorized Remdesivir compassionate use for the
treatment of adults and children with severe COVID-19 disease who do not respond to other …

… The search yielded 2191 RCTs; after applying eligibility criteria, 12 full-text trials assessing
various treatment options for COVID-19 were included (Fig. 1). Risk of bias assessment of …

… mortality rate in adults aged 70 years or older hospitalized by COVID-19 pneumonia.
Baricitinib could be a good treatment in older adult populations with severe COVID-19, and could …

… of all intermediate and long-term COVID-19 sequelae affecting formerly healthy adults. …
adults aged 18–50 years as they make up the majority of the working population. COVID-19 in …

… The selection of treatments in this review is based on the 7th edition of the ‘COVID-19
diagnosis and treatment guideline’ issued by the National Health Commission (NHC) of the …

… patients over 60 years with severe COVID 19 (with SpO2 ≤ 94… We did not find evidence of
interaction between treatment … study is underpowered to detect treatment differences in the ITT …

… Can you clarify how many days on average elapsed between the diagnosis of COVID-19
and the beginning of treatment with ivermectin? It seems as if 2 "bonus" days are not bad at all. …

… effective antiviral treatment for COVID-19. Although most of the COVID-19 patients have mild
… In a prospective randomized trial of 30 adults with COVID-19 in China, 15 patients treated …